scispace - formally typeset
M

Michael A. Palladino

Researcher at Nereus Pharmaceuticals

Publications -  177
Citations -  19198

Michael A. Palladino is an academic researcher from Nereus Pharmaceuticals. The author has contributed to research in topics: Proteasome inhibitor & Bortezomib. The author has an hindex of 57, co-authored 176 publications receiving 18857 citations. Previous affiliations of Michael A. Palladino include Genentech & Memorial Sloan Kettering Cancer Center.

Papers
More filters
Journal ArticleDOI

Selective activation of liver X receptors by acanthoic acid-related diterpenes.

TL;DR: Results show the ability of certain acanthoic acid diterpenes to activate efficiently both LXRs and suggest that these compounds can exert beneficial effects from a cardiovascular standpoint through LXR-dependent mechanisms.
Journal ArticleDOI

Synthesis and structure-activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents.

TL;DR: KPU-105 (4), a potent anti-microtubule agent that contains a benzophenone was derived from the diketopiperazine-type vascular disrupting agent (VDA) plinabulin 3, which displays colchicine-like tubulin depolymerization activity, was modified and obtained a 4-fluorobenzophenone derivative 16j that inhibited tumor cell growth in vitro with a subnanomolar IC(50) value.
Patent

Antibodies against type 2 tumor necrosis factor receptor

TL;DR: In this article, the use of monoclonal antibodies against type 2 tumor necrosis factor receptor (TN-R2) for the stimulation of human T-cell proliferation is described.
Patent

Gamma interferon-interleukin-2 synergism

TL;DR: In this article, compositions containing therapeutically synergistic mixtures of purified gamma interferon and purified interleukin-2 are provided for treatment of tumor-bearing hosts.
Patent

Analogs of dehydrophenylahistins and their therapeutic use

TL;DR: In this article, compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed, as well as methods for making such compounds.